Enquire
Services

Clinical-stage biotech · Cambridge

Services

How we can help

01 / 04

HLX-101

Inherited retinal disease. Phase II, enrolling.

HLX-101
02 / 04

HLX-204

Rare metabolic disorder. Phase I/II.

HLX-204
03 / 04

HLX-310

Neuromuscular disease. IND-enabling studies.

HLX-310
04 / 04

Platform

Next-generation capsids designed with machine learning.

Platform
In detail

Every detail, considered

Phase IILead programme
AAVDelivery platform
Helix Biotech
GMPManufacturing partner
MHRAApproved trials
Partnerships

Work with Helix

Academic

Research partners

Collaboration

  • Shared IP framework
  • Lab access
  • Joint publications

Commercial

Industry

Licensing

  • Regional rights
  • Co-development
  • Platform access
Questions

Good to know

How do we begin?
With a private conversation, in person or by video, at a time that suits you. There is no obligation.
Do you work internationally?
Yes. We regularly work across Europe, the Gulf and North America, and travel to you.
How is discretion handled?
Every engagement is covered by a confidentiality agreement. We never publish client names without written consent.
How long does it take?
It depends on the scope. We give you a clear timetable at the start and keep to it.
By appointment

Begin a private conversation

Tell us what you have in mind. A director will reply personally within one working day.